ATE473216T1 - Hydroxymorpholinonderivat und dessen medizinische verwendung - Google Patents
Hydroxymorpholinonderivat und dessen medizinische verwendungInfo
- Publication number
- ATE473216T1 ATE473216T1 AT03745432T AT03745432T ATE473216T1 AT E473216 T1 ATE473216 T1 AT E473216T1 AT 03745432 T AT03745432 T AT 03745432T AT 03745432 T AT03745432 T AT 03745432T AT E473216 T1 ATE473216 T1 AT E473216T1
- Authority
- AT
- Austria
- Prior art keywords
- hydroxymorpholinone
- derivative
- calpain
- medical use
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
- C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002097186 | 2002-03-29 | ||
PCT/JP2003/003910 WO2003082837A1 (fr) | 2002-03-29 | 2003-03-27 | Derive de l'hydroxymorpholinone et ses utilisations medicales |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE473216T1 true ATE473216T1 (de) | 2010-07-15 |
Family
ID=28671859
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03745432T ATE473216T1 (de) | 2002-03-29 | 2003-03-27 | Hydroxymorpholinonderivat und dessen medizinische verwendung |
Country Status (10)
Country | Link |
---|---|
US (1) | US7223755B2 (de) |
EP (1) | EP1491537B1 (de) |
JP (1) | JP4520747B2 (de) |
KR (1) | KR101032006B1 (de) |
CN (1) | CN100422161C (de) |
AT (1) | ATE473216T1 (de) |
AU (1) | AU2003236180A1 (de) |
DE (1) | DE60333268D1 (de) |
ES (1) | ES2348534T3 (de) |
WO (1) | WO2003082837A1 (de) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT2121578T (lt) | 2007-01-12 | 2016-11-25 | Novartis Ag | 5-bifenil-4-amino-2-metilpentano rūgšties gavimo būdas |
AU2011295170B2 (en) | 2010-08-23 | 2014-12-18 | Novartis Ag | Process for the preparation of intermediates for the manufacture of NEP inhibitors |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0629229B2 (ja) * | 1987-11-05 | 1994-04-20 | サントリー株式会社 | システインプロティナーゼ阻害剤 |
PL171704B1 (pl) * | 1992-05-20 | 1997-06-30 | Senju Pharma Co | Sposób wytwarzania srodka farmaceutycznego do leczenia lub profilaktyki zacmy PL |
JP2825172B2 (ja) | 1992-07-10 | 1998-11-18 | 東京エレクトロン株式会社 | 減圧処理装置および減圧処理方法 |
ATE230275T1 (de) | 1995-10-25 | 2003-01-15 | Senju Pharma Co | Angiogense-inhibitor |
CA2274464C (en) * | 1996-12-11 | 2007-01-02 | Basf Aktiengesellschaft | Ketobenzamides as calpain inhibitors |
IL159125A0 (en) * | 2001-06-01 | 2004-05-12 | Axys Pharm Inc | Novel compounds and compositions as cathepsin inhibitors |
-
2003
- 2003-03-27 ES ES03745432T patent/ES2348534T3/es not_active Expired - Lifetime
- 2003-03-27 EP EP03745432A patent/EP1491537B1/de not_active Expired - Lifetime
- 2003-03-27 KR KR1020047015391A patent/KR101032006B1/ko not_active IP Right Cessation
- 2003-03-27 AT AT03745432T patent/ATE473216T1/de not_active IP Right Cessation
- 2003-03-27 AU AU2003236180A patent/AU2003236180A1/en not_active Abandoned
- 2003-03-27 DE DE60333268T patent/DE60333268D1/de not_active Expired - Lifetime
- 2003-03-27 US US10/509,253 patent/US7223755B2/en not_active Expired - Fee Related
- 2003-03-27 JP JP2003580305A patent/JP4520747B2/ja not_active Expired - Fee Related
- 2003-03-27 WO PCT/JP2003/003910 patent/WO2003082837A1/ja active Application Filing
- 2003-03-27 CN CNB038122707A patent/CN100422161C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
DE60333268D1 (de) | 2010-08-19 |
ES2348534T3 (es) | 2010-12-09 |
CN1656084A (zh) | 2005-08-17 |
KR20040095339A (ko) | 2004-11-12 |
CN100422161C (zh) | 2008-10-01 |
EP1491537A8 (de) | 2005-03-30 |
EP1491537A4 (de) | 2007-10-10 |
US7223755B2 (en) | 2007-05-29 |
AU2003236180A1 (en) | 2003-10-13 |
EP1491537B1 (de) | 2010-07-07 |
JP4520747B2 (ja) | 2010-08-11 |
WO2003082837A1 (fr) | 2003-10-09 |
JPWO2003082837A1 (ja) | 2005-08-04 |
KR101032006B1 (ko) | 2011-05-02 |
US20050176704A1 (en) | 2005-08-11 |
EP1491537A1 (de) | 2004-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE449090T1 (de) | Substituierte piperazin- und diazepanderivate zur verwendung als histamin h3 rezeptormodulatoren | |
ATE344033T1 (de) | Vinylphenyl-derivate als glk-aktivatoren | |
ECSP066311A (es) | Derivados de la piperazina y su uso como agentes terapéuticos | |
DK1288205T3 (da) | Nye phenylalanin-derivater | |
NO20065904L (no) | Terapeutiske forbindelser | |
EA200101166A1 (ru) | Ингибиторы металлопротеаз | |
NO20061214L (no) | 2,4-pyrimidindiaminer nyttige i behandling av neoplastiske sykdomme,r inflammatoriske forstyrrelser og immunsystemforstyrrelser | |
NO20060973L (no) | Pyridylderivater og deres anvendelse som tempeutiske midler | |
MX2007003321A (es) | Derivados heterociclicos y su uso como agentes terapeuticos. | |
CY1105621T1 (el) | Νεα ετεροκυκλικα παραγωγα φθορογλυκοζιτου, φαρμακα που περιεχουν τις ενωσεις αυτες και η χρηση τους | |
NO20055977L (no) | Nye benzimidazolderivater | |
UA84146C2 (ru) | Амиды пирролопиридин-2-карбоновой кислоты как ингибиторы гликогенфосфорилазы, способ их получения, фармацевтическая композиция и их применение как терапевтических агентов для лечения заболеваний | |
DE602004028150D1 (de) | Aminopyrazolderivate als gsk-3-inhibitoren | |
BRPI0418939A (pt) | derivados de nicotinamida e sua utilização como agentes terapêuticos | |
ATE416157T1 (de) | Inhibitoren von integrin alpha-v-beta-6 | |
ATE424821T1 (de) | Pyrrolopyridin-2-karbonsäureamide | |
DE60121461D1 (de) | Kondensierte pyridoindolderivate | |
DE60329330D1 (de) | Piperidin- und pyrrolidin-derivate alsantagonisten des histamin-h3-rezeptors | |
ATE507226T1 (de) | 1,3,4-oxadiazol-2-one als ppar-delta-modulatoren und deren verwendung | |
ATE364044T1 (de) | 5ht2c rezeptor agonisten zur behandlung von diabetes und fettleibigkeit | |
EA200602154A1 (ru) | Пиридин-4-илэтинилимидазолы и -пиразолы как антагонисты рецептора mglu5 | |
ATE473216T1 (de) | Hydroxymorpholinonderivat und dessen medizinische verwendung | |
EA200501557A1 (ru) | Новый способ синтеза (2s)-индолин-2-карбоновой кислоты и использование в синтезе периндоприла | |
CY1110613T1 (el) | Υποκατεστημενες θειαζολες και η χρησιμοποιηση τους για την παρασκευη φαρμακων | |
ATE440835T1 (de) | Heterozyklische harnstoff-derivate für die behandlung von schmerzen. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |